Good evening :)
Place Order
Add to Watchlist

Dr Reddy's Laboratories Ltd

DRREDDY

Dr Reddy's Laboratories Ltd

DRREDDY
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,06,933 cr, stock is ranked 83
Low RiskStock is 1.47x as volatile as Nifty
1,283.650.29% (-3.70)
1,283.650.29% (-3.70)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,06,933 cr, stock is ranked 83
Low RiskStock is 1.47x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹1,06,933 cr, stock is ranked 83
Low RiskStock is 1.47x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
20.033.780.62%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.356.540.51%

Forecast & Ratings

Detailed Forecast 
35%
Analysts have suggested that investors can buy this stock

from 31 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 12.81%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 7.21% to 7.67%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 23.39%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue15,863.3014,367.6014,436.2015,829.5018,193.7019,386.9022,099.9025,762.2028,920.1031,011.50
Raw Materialssubtract3,854.203,819.804,081.004,770.205,530.706,869.407,796.107,586.808,889.2022,024.20
Power & Fuel Costsubtract315.20330.10329.30329.10314.80320.50390.50477.40533.90
Employee Costsubtract3,117.403,106.803,214.903,356.203,380.203,629.903,885.804,646.605,030.10
Selling & Administrative Expensessubtract3,007.003,287.102,106.102,235.302,184.202,398.302,976.103,199.303,710.20
Operating & Other expensessubtract1,689.201,180.102,198.501,579.203,636.701,959.502,729.002,410.601,914.60
Depreciation/Amortizationsubtract938.901,026.601,077.201,134.801,163.101,228.801,165.201,250.201,470.001,518.80
Interest & Other Itemssubtract82.6063.4078.8088.9098.3097.0095.80142.80171.10234.20
Taxes & Other Itemssubtract728.20261.60403.60385.80-140.30931.90878.901,541.201,623.101,895.50
EPS24.9915.3711.4223.5024.3923.4826.2454.1566.9364.01
DPS4.004.004.004.005.005.006.008.008.008.00
Payout ratio0.160.260.350.170.200.210.230.150.120.12

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Jun 21PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Dr Reddy's Laboratories Ltd19.173.780.62%
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare DRREDDY with any stock or ETF
Compare DRREDDY with any stock or ETF
DRREDDY
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding26.64%10.86%10.61%41.75%10.13%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep39.54%42.21%43.96%44.49%42.27%41.75%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Dr Reddy's Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Parag Parikh Flexi Cap Fund - Growth - Direct Plan

Growth
0.7370%0.96%-0.08%21/91 (+3)
ICICI Prudential Value Discovery Fund - Growth - Direct Plan

Growth
0.6680%1.40%1.17%17/101 (+23)
Nippon India Large Cap Fund - Growth - Direct Plan

Growth
0.5362%1.68%-0.23%15/76 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Dr Reddy's Laboratories Ltd

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

DRREDDY has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.62%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.24 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 16, 2024

Final
Final | Div/Share: ₹40.00

Dividend/Share

₹40.00

Ex DateEx Date

Jul 16, 2024

Cash Dividend

Ex DateEx DateJul 11, 2023

Final
Final | Div/Share: ₹40.00

Dividend/Share

₹40.00

Ex DateEx Date

Jul 11, 2023

Cash Dividend

Ex DateEx DateJul 11, 2022

Final
Final | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Jul 11, 2022

Cash Dividend

Ex DateEx DateJul 9, 2021

Final
Final | Div/Share: ₹25.00

Dividend/Share

₹25.00

Ex DateEx Date

Jul 9, 2021

Cash Dividend

Ex DateEx DateJul 13, 2020

Final
Final | Div/Share: ₹25.00

Dividend/Share

₹25.00

Ex DateEx Date

Jul 13, 2020

News & Opinions
Spotlight
Dr Reddys Laboratories Ltd spurts 2.25%

Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1300.85, up 2.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.85% on the day, quoting at 24419.55. The Sensex is at 80155.08, up 0.85%. Dr Reddys Laboratories Ltd has dropped around 1.6% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has dropped around 0.45% in last one month and is currently quoting at 22661.25, up 0.94% on the day. The volume in the stock stood at 29.93 lakh shares today, compared to the daily average of 6.7 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1301, up 2.14% on the day. Dr Reddys Laboratories Ltd is up 20.35% in last one year as compared to a 25.83% spurt in NIFTY and a 49.79% spurt in the Nifty Pharma index.The PE of the stock is 25.77 based on TTM earnings ending June 24.Powered by Capital Market - Live

3 days agoCapital Market - Live
Spotlight
Dr Reddy's Q2 PAT slides 15% YoY to Rs 1,255 crore

Total revenue from operations stood at Rs 8,038.2 crore in Q2 FY25, up 16.45% as agasint Rs 6,902.6 crore posted in Q2 FY24. The revenue growth was primarily driven by growth in global generics revenues. Consolidated profit before tax rose marginally to Rs 1,917.4 crore in the second quarter of FY25 as against Rs 1916.7 crore posted in Q2 FY24. EBITDA grew 4.53% to Rs 2,280.3 crore in Q2 FY25 as against Rs 2,181.3 crore recorded in the corresponding quarter previous year. EBITDA margin reduced to 28.4% in Q2 FY25 as against 31.7% posted in Q2 FY24. Q2 FY25 gross margin stood at 59.6%, up 92 bps YoY, primarily of improvement in product mix and overhead leverage, partly offset by price erosion. Selling, general & administrative (SG&A) expenses for Q2 FY25 were at Rs 2,300.7 crore, YoY increase of 22.41%. Research & development (R&D) expenses in second quarter of FY25 stood at Rs 727.10 crore, 28.7% of revenue. During the quarter, revenues from Emerging Markets segment stood at Rs 1,455.4 crore, year on year increase of 19.65%, growth is attributable to market share expansion as well as new product launches. Revenues from India market during the quarter stood at Rs 1,397.1 crore, year on year increase of 17.79%, growth was led by revenues from the vaccine portfolio in-licensed from Sanofi, new products launched as well as price increases. During the quarter, company launched three new brands in the country, taking the year-to-date total to 16. Revenues from North America market was at Rs 3,728.1 crore, year on year rise of 17.32%. The growth was largely on account of increase in sales volumes, partly offset by price erosion. During the quarter, revenue from Europe market was at Rs 577 crore, year on year growth of 9.15%. The growth was primarily on account of leveraging the portfolio to launch new products, partly offset by price erosion. Revenues from Global Generics (GG) during the quarter grew 17.17% YoY to Rs 7,157.6 crore, primarily driven by improved sales volumes and new product launches. Sequential growth was primarily driven by Emerging Markets and Europe. Revenues from Pharmaceutical Services and Active Ingredients (PSAI) rose 19.51% to Rs 840.70 crore in Q2 FY25, mainly driven by momentum in base business volumes, growth in services business and revenues from new products. Free cash-flow for Q2 FY25 stood at Rs 200 crore while net cash surplus for the company was at Rs 1,890 crore as on 30 September 2024. Capital expenditure for second quarter of FY25 stood at Rs 740 crore. On half year basis, the company's net profit declined 8.28% to Rs 2,648.1 crore on 15.18% rise in total revenue from operations to Rs 15,734 crore in H1 FY25 over H1 FY24. Commenting on the results, co-chairman & MD, G V Prasad said, We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation. Meanwhile, the company's board approved fund infusion by way of investment in equity shares of Dr. Reddy's Laboratories LLC, Russia, a step-down wholly-owned subsidiary, upto an amount of Rs 600 crore. The fund will be used for working capital requirements. Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products. The scrip rose 0.36% to close at Rs 1,272.55 on the BSE.Powered by Capital Market - Live

4 days agoCapital Market - Live
Earnings
Dr Reddy's Laboratories consolidated net profit declines 15.28% in the September 2024 quarter

Net profit of Dr Reddy's Laboratories declined 15.28% to Rs 1255.70 crore in the quarter ended September 2024 as against Rs 1482.20 crore during the previous quarter ended September 2023. Sales rose 16.51% to Rs 8016.10 crore in the quarter ended September 2024 as against Rs 6880.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales8016.106880.20 17 OPM %25.9029.19 - PBDT2314.402292.20 1 PBT1917.401916.70 0 NP1255.701482.20 -15 Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
Aurigene Oncology receives nod for Phase 2 clinical trial for Ribrecabtagene autoleucel

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study - India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients. After reviewing the Phase 1 data, the Indian Regulatory Agency i.e., Drugs Controller General of India (DCGI), has given the nod to commence Phase 2 part of the trial. These results of Phase 1 were presented at the 21st annual meeting of the International Myeloma Society at Rio De Janeiro, Brazil, held recently. Ribrecabtagene autoleucel is an autologous anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen binding domain and lentivirus as a vector. DRL-1801 for the clinical trials is manufactured at the CAR-T GMP manufacturing facility at Aurigene Oncology, Bangalore. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Dr Reddys announces incorporation of new step-down subsidiary in Denmark

Dr. Reddy's Laboratories SA, Switzerland, (DRSA) a wholly owned subsidiary of  Dr Reddys Laboratories , has incorporated a new wholly-owned subsidiary in Denmark, named 'Dr. Reddy's Denmark ApS' on 04 October 2024. Accordingly, Dr. Reddy's Denmark ApS is a step-down wholly-owned subsidiary of the Company. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Dr Reddys acquires Haleon plc brands in NRT category

Dr Reddys Laboratories announced that its wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland has completed the acquisition of Haleon plc's global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside of the United States, through the purchase of shares of Northstar Switzerland SARL (Northstar Switzerland), a Haleon group company. The cost of acquisition is a payment of upfront cash consideration of GBP 458 million. As part of this acquisition, Northstar Switzerland along with its wholly owned subsidiaries North Star OpCo Limited (United Kingdom) and North Star Sweden AB (Sweden) are now wholly-owned step-down subsidiaries of the Company with effect from 30 September 2024. The acquired portfolio consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product - Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The portfolio is inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Dr Reddys Laboratories schedules board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 5 November 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Dr Reddys Laboratories Ltd down for fifth straight session

Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 6505.2, down 0.95% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Dr Reddys Laboratories Ltd has lost around 6.61% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 3.35 lakh shares today, compared to the daily average of 3.4 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6530.4, down 0.71% on the day. Dr Reddys Laboratories Ltd jumped 15.85% in last one year as compared to a 27.59% rally in NIFTY and a 47.81% spurt in the Nifty Pharma index.The PE of the stock is 26.6 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Live Market Update
Market at day's low; European mkt decline

The domestic equity benchmarks traded with deep cuts in afternoon trade. The Nifty traded below the 24,900 level after hitting the day's high of 25,168.75 in early trade. Barring the Nifty Metal index, all the other sectoral indices on the NSE traded in red. At 13:30 IST, the barometer index, the S&P BSE Sensex, slumped 931.43 points or 1.14% to 81,262.79. The Nifty 50 index dropped 272.55 points or 1.08% to 24,872.55. In the broader market, the S&P BSE Mid-Cap index fell 1.06% and the S&P BSE Small-Cap index declined 0.68%. The market breadth was weak. On the BSE, 1,356 shares rose and 2,494 shares fell. A total of 117 shares were unchanged. Gainers & Losers: Asian Paints (up 1.04%), Bajaj Finance (up 0.97%), JSW Steel (up 0.73%), LTIMindtree (up 0.58%) and Hindustan Unilever (up 0.55%) were major Nifty gainers. State Bank of India (down 3.68%), HCL Technologies (down 2.56%), Bharat Petroleum Corporation (down 2.31%), ITC (down 2.23%) and Grasim Industries (down 2.21%) were major Nifty losers. Stocks in Spotlight: Dr Reddy's Laboratories shed 0.38%. The pharma major announced that it has received the establishment inspection report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. Angel One slipped 2.23%. The company announced that its client base jumped 62.9% to 26.65 million in August 2024 as against 16.36 million recorded in August 2023. Matrimony.com shed 0.02%. The matchmaking services provider announced that its board has approved a share buyback of up to Rs 72 crore at a price of Rs 1,025 per equity share through tender offer route. VA Tech Wabag rallied 3.62% after the company announced that it has bagged a mega order worth $317 million (approximately Rs 2,700 crore) from the Saudi Water Authority (SWA). KEC International rose 1.15% after the company secured new orders of Rs 1,423 crore for design, supply and installation of 380 kV transmission lines in Saudi Arabia. Rites lost 0.03%. The company has been declared as L-1 bidder by UP State Bridge Corporation for consultancy services for construction of civil works in Uttar Pradesh. Global Markets: European and Asian stocks declined on Friday as investors shifted their focus to the upcoming U.S. payrolls report. The report is expected to shed light on the potential magnitude of a rate cut by the Federal Reserve later this month. Japan's household spending data for July rose 0.1% in real terms from the previous year as compared to a 1.4% fall in June. Data from the Japan's statistics bureau said the average household monthly expenditure for July 2024 was 290,931 yen ($2,031.35), up 3.3% in nominal terms from the previous year. Hong Kong's markets will be shut today due to Super Typhoon Yagi. Overnight in the U.S., all three major indexes declined amid ongoing concerns about the economic outlook. The S&P 500 fell by 0.3%, extending its losing streak to three days, while the Dow Jones Industrial Average dropped 0.54%. However, the tech-heavy Nasdaq Composite managed a modest gain of 0.25%. Adding to the economic uncertainty, ADP reported that private sector job growth in August was the weakest in over three and a half years. Companies hired only 99,000 workers, falling short of both the downwardly revised July figure and market expectations. This marked the weakest month for job growth since January 2021, according to data from the payrolls processing firm. Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Dr Reddy's Labs Andhra Pradesh facility gets EIR from USFDA

The inspection has been classified as voluntary action indicated (VAI) and has been closed accordingly said the firm. On 7 June 2024, USFDA had issued form 483 with four observations post inspection at its Andhra Pradesh facility. The good manufacturing practices (GMP) inspection was conducted from 30 May 2024 to 7 June 2024 at the API manufacturing facility. Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products. The company's consolidated net profit shed marginally to Rs 1,392.40 crore in Q1 FY25 as against 1,405 crore posted in Q1 FY24. However revenue from operations jumped 13.9% YoY to Rs 7,672.70 crore in Q1 FY25. Shares of Dr.Reddy's Laboratories shed 0.23% to Rs 6,682on the BSE. Powered by Capital Market - Live

2 months agoCapital Market - Live